HSKA - ヘスカ (Heska Corporation) ヘスカ

 HSKAのチャート


 HSKAの企業情報

symbol HSKA
会社名 Heska Corp. (ヘスカ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 事業概要 ヘスカ(Heska Corporation)は獣医向けの診断と特殊製品の販売に従事する会社。同社はコアコンパニオンアニマルヘルス(CCA)とその他のワクチン、医薬品と製品(OVP)事業という2つの事業セグメントを運営する。CCA事業セグメントは、主に犬と猫に使用される血液検査機器と消耗品、デジタル画像製品、ソフトウェアとサービス、ローカルとクラウドベースのデータサービス、アレルギー検査と免疫療法、並びに病院内診断テストとワーム予防製品などの単回使用製品を含む。OVP事業セグメントは、牛用、並びに馬、ブタ、鳥類、猫及び犬を含む他の種の動物向けの個人ラベルワクチンと薬品を含む。すべてのOVP製品はサードパーティのラベルの下で第三者によって販売される。同社は、犬や猫のヘルスケア分野における獣医師へのサポートを中心とする。同社は、獣医向けの血液検査と他の器具のラインを提供し、他の動物健康会社向けの生物学的製剤と医薬品を生産する。   ヘスカは米国の獣医製品メ―カ―。動物向けに医薬品ヘルスケア製品の開発、製造、販売、サポ―トを行う。犬・猫などのペット動物を対象に血液検査機器、フィラリア診断テスト、フィラリア予防製品、アレルギ―免疫療法製品、アレルギ―検査、およびデジタル画像製品を提供する。また、牛や小型哺乳類を含む他の動物向けにワクチンや医薬品を提供する。   Heska Corporation manufactures, develops and sells advanced veterinary diagnostic and specialty healthcare products through its two business segments: North America and International. Both segments include Point of Care Lab testing instruments and consumables, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The North America segment also includes private label vaccine and pharmaceutical production under third-party agreements and channels, primarily for herd animal health.
本社所在地 3760 Rocky Mountain Avenue Loveland CO 80538 USA
代表者氏名 Sharon J. Larson シャロンJ.ラーソン
代表者役職名 Independent Chairman of the Board
電話番号 +1 970-493-7272
設立年月日 1988年
市場名 NASDAQ Small Cap
ipoyear 1997年
従業員数 345人
url www.heska.com
nasdaq_url https://www.nasdaq.com/symbol/hska
adr_tso
EBITDA EBITDA(百万ドル) 19.84200
終値(lastsale) 97.06
時価総額(marketcap) 727735594.46
時価総額 時価総額(百万ドル) 751.87850
売上高 売上高(百万ドル) 127.05000
企業価値(EV) 企業価値(EV)(百万ドル) 744.22250
当期純利益 当期純利益(百万ドル) 11.96300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Heska Corp revenues decreased 1% to $62.4M. Net income decreased 49% to $4.1M. Revenues reflect Other Vaccines Pharmaceuticals_Products segment decrease of 32% to $9M. Net income also reflects Other Vaccines Pharmaceuticals_Products segment loss totaling $712K vs. income of $3.7M. Basic Earnings per Share excluding Extraordinary Items decreased from $1.13 to $0.57.

 HSKAのテクニカル分析


 HSKAのニュース

   Heska Earnings Perspective: Return On Capital Employed  2023/05/19 14:48:34 Benzinga
Benzinga Pro data, Heska (NASDAQ: HSKA ) reported Q1 sales of $62.38 million. Earnings fell to a loss of $10.12 million, resulting in a 139.87% decrease from last quarter. In Q4, Heska brought in $66.34 million in sales but lost $4.22 million in earnings. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company … Full story available on Benzinga.com
   Recap: Heska Q1 Earnings  2023/05/05 13:20:08 Benzinga
Heska (NASDAQ: HSKA ) reported its Q1 earnings results on Friday, May 5, 2023 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Heska beat estimated earnings by 134.0%, reporting an EPS of $0.17 versus an … Full story available on Benzinga.com
   Heska Non-GAAP EPS of $0.17, revenue of $62.4M  2023/05/05 12:18:57 Seeking Alpha
Heska press release (NASDAQ:HSKA): Q1 Non-GAAP EPS of $0.17.Revenue of $62.4M (-3.7% Y/Y).
   Heska: Q1 Earnings Snapshot  2023/05/05 12:11:09 WTOP
LOVELAND, Colo. (AP) — LOVELAND, Colo. (AP) — Heska Corp. (HSKA) on Friday reported a loss of $10.1 million in…
   Heska Corporation Reports First Quarter 2023 Results  2023/05/05 12:00:00 PR Newswire
LOVELAND, Colo., May 5, 2023 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska" or "Company"), a leading global provider of advanced veterinary diagnostic and specialty products, reported financial results for its first quarter ended March 31, 2023. First Quarter 2023 and Year Over…
   Morgan Stanley Downgrades Heska Corp. to Underweight  2023/01/06 09:47:03 Investing.com
https://www.investing.com/news/pro/morgan-stanley-downgrades-heska-corp-to-underweight-432SI-2974469
   Heska Corporation (HSKA) Could Be Possessing A Gold Mine  2022/12/17 12:30:00 Stocks Register
Heska Corporation (NASDAQ:HSKA) concluded the trading at $62.71 on Friday, December 16 with a rise of 0.97% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $62.11 and 5Y monthly beta was reading 1.42 with its price kept floating in the range … Heska Corporation (HSKA) Could Be Possessing A Gold Mine Read More »
   Heska''s Return On Capital Employed Overview  2022/12/06 14:48:52 Benzinga
According to Benzinga Pro data, during Q3, Heska (NASDAQ: HSKA ) posted sales of $61.49 million. Earnings were up 91.69%, but Heska still reported an overall loss of $436 thousand. Heska collected $64.68 million in revenue during Q2, but reported earnings showed a $5.25 million loss. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is a … Full story available on Benzinga.com
   Heska: Compelling Core Offering, But Fairly Valued  2022/12/06 08:42:42 Seeking Alpha
Heska has various revenue streams with niche expertise in the advanced veterinary diagnostics market. See why we rate HSKA a hold.
   Heska Corporation (HSKA) Q3 2022 Earnings Call Transcript  2022/11/12 20:37:04 Seeking Alpha
Heska Corporation (NASDAQ:NASDAQ:HSKA) Q3 2022 Results Conference Call November 08, 2022 11:00 AM ET Company Participants Jon Aagaard - Director, IR Kevin Wilson - President and CEO…
   Morgan Stanley Downgrades Heska Corp. to Underweight  2023/01/06 09:47:03 Investing.com
https://www.investing.com/news/pro/morgan-stanley-downgrades-heska-corp-to-underweight-432SI-2974469
   Heska Corporation (HSKA) Could Be Possessing A Gold Mine  2022/12/17 12:30:00 Stocks Register
Heska Corporation (NASDAQ:HSKA) concluded the trading at $62.71 on Friday, December 16 with a rise of 0.97% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $62.11 and 5Y monthly beta was reading 1.42 with its price kept floating in the range … Heska Corporation (HSKA) Could Be Possessing A Gold Mine Read More »
   Heska''s Return On Capital Employed Overview  2022/12/06 14:48:52 Benzinga
According to Benzinga Pro data, during Q3, Heska (NASDAQ: HSKA ) posted sales of $61.49 million. Earnings were up 91.69%, but Heska still reported an overall loss of $436 thousand. Heska collected $64.68 million in revenue during Q2, but reported earnings showed a $5.25 million loss. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is a … Full story available on Benzinga.com
   Heska: Compelling Core Offering, But Fairly Valued  2022/12/06 08:42:42 Seeking Alpha
Heska has various revenue streams with niche expertise in the advanced veterinary diagnostics market. See why we rate HSKA a hold.
   Heska Corporation (HSKA) Q3 2022 Earnings Call Transcript  2022/11/12 20:37:04 Seeking Alpha
Heska Corporation (NASDAQ:NASDAQ:HSKA) Q3 2022 Results Conference Call November 08, 2022 11:00 AM ET Company Participants Jon Aagaard - Director, IR Kevin Wilson - President and CEO…

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 ヘスカ HSKA Heska Corporation)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)